TABLE OF CONTENTS | View Digital Edition
HEALTH ECONOMICS
Healthcare Reform: Cost-Containment Not Very Likely
The Costs of Multiple Myeloma Treatment Vary Widely Pegfilgrastim with Transplant: Upfront Cost May Be Offset
For MDS Treatment, Azacitidine Enhances Cost-Effectiveness Compared with Decitabine
Bortezomib Cost-Effective for Newly Diagnosed Patients with Multiple Myeloma
Alemtuzumab Contributes 39% to Treatment Costs in CLL
LYMPHOMA
New Regimen Challenges Standard Treatment of Indolent Lymphoma
In Challenging B-Cell Lymphoma, Aggressive Chemotherapy plus Rituximab Show Best Outcomes
Treatment Is Beneficial in Older Patients with Advanced Lymphoma
Hodgkin’s Lymphoma: No Changes in Standard of Care, but Emerging Therapies Are Promising
Adding Rituximab to Standard Therapy in Hodgkin’s Lymphoma Improves Outcomes
Novel Agent Shows Impressive Outcomes in Aggressive NHL
How Much Rituximab Is Necessary in Advanced NHL?
Long-Term Survival Achieved with Tositumomab/I-131
Emerging Strategies for Mantle-Cell Lymphoma
LEUKIMIA
First Head-to-Head Comparison of Targeted TKIs
Intermittent Dosing of Dasatinib May Cut Toxicity, Allow Continued Treatment in CML
Bendamustine-Rituximab Combo an Effective First-Line Therapy for CLL
Statins Delay Treatment in CLL
Second-Generation TKIs Effective, Safe for Relapsed ALL
Advances in Treating MDS
Adding Alemtuzumab to Fludarabine Doubles PFS in Relapsed CLL
Antifungal Prophylaxis in AML Patients Receiving Induction Chemotherapy
MULTIPLE MYELOMA
Maintenance Therapy an Emerging Theme in Myeloma
High-Risk Smoldering Myeloma Responds to Treatment
Multiple Myeloma Management in 2010
Weekly Bortezomib Effective, Less Toxic
OTHER ASH HIGHLIGHTS
Hematologic Drug Pipeline Diverse and Promising
Investigational Alternatives to Warfarin Prevent VTE Events
Stem-Cell Mobilization Strategies: What Works, What Doesn’t
Positive Long-Term Data for 2 ITP Treatments
| Attachment | Size |
|---|---|
| AHDB_feb_ASH2009.pdf | 4.15 MB |